MARK2
Serine/threonine-protein kinase MARK2
Also known as: EMK1, MARK2_HUMAN, PAR-1, PAR-1B, Par1b
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q7KZI7
- Gene
- MARK2
- Ensembl
- ENSG00000072518
- Chromosome
- 11
- Canonical length
- 788 aa
- Protein class
- Enzymes, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Plasma membrane
- Quaternary structure
- Homodimer
OverviewNCBI Gene
This gene encodes a member of the Par-1 family of serine/threonine protein kinases. The protein is an important regulator of cell polarity in epithelial and neuronal cells, and also controls the stability of microtubules through phosphorylation and inactivation of several microtubule-associating proteins. The protein localizes to cell membranes. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2009]
Canonical amino-acid sequenceUniProt
788 residues, UniProt reviewed canonical sequence.
>Q7KZI7|MARK2
1 MSSARTPLPT LNERDTEQPT LGHLDSKPSS KSNMIRGRNS ATSADEQPHI GNYRLLKTIG
61 KGNFAKVKLA RHILTGKEVA VKIIDKTQLN SSSLQKLFRE VRIMKVLNHP NIVKLFEVIE
121 TEKTLYLVME YASGGEVFDY LVAHGRMKEK EARAKFRQIV SAVQYCHQKF IVHRDLKAEN
181 LLLDADMNIK IADFGFSNEF TFGNKLDTFC GSPPYAAPEL FQGKKYDGPE VDVWSLGVIL
241 YTLVSGSLPF DGQNLKELRE RVLRGKYRIP FYMSTDCENL LKKFLILNPS KRGTLEQIMK
301 DRWMNVGHED DELKPYVEPL PDYKDPRRTE LMVSMGYTRE EIQDSLVGQR YNEVMATYLL
361 LGYKSSELEG DTITLKPRPS ADLTNSSAPS PSHKVQRSVS ANPKQRRFSD QAAGPAIPTS
421 NSYSKKTQSN NAENKRPEED RESGRKASST AKVPASPLPG LERKKTTPTP STNSVLSTST
481 NRSRNSPLLE RASLGQASIQ NGKDSLTMPG SRASTASASA AVSAARPRQH QKSMSASVHP
541 NKASGLPPTE SNCEVPRPST APQRVPVASP SAHNISSSGG APDRTNFPRG VSSRSTFHAG
601 QLRQVRDQQN LPYGVTPASP SGHSQGRRGA SGSIFSKFTS KFVRRNLSFR FARRNLNEPE
661 SKDRVETLRP HVVGSGGNDK EKEEFREAKP RSLRFTWSMK TTSSMEPNEM MREIRKVLDA
721 NSCQSELHEK YMLLCMHGTP GHEDFVQWEM EVCKLPRLSL NGVRFKRISG TSMAFKNIAS
781 KIANELKLLocalizationUniProt · AlphaFold · HPA
Whether an antibody against MARK2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.47
- Highest tissue expression
- 42 nTPM
Expression across tissuesHPA
Tissue
- esophagus: 42 nTPM
- skin: 33 nTPM
- salivary gland: 26 nTPM
- duodenum: 25 nTPM
- colon: 24 nTPM
- small intestine: 24 nTPM
Single-cell type
- neutrophils: 378 nCPM
- esophageal apical cells: 215 nCPM
- neutrophil progenitors: 169 nCPM
- syncytiotrophoblasts: 143 nCPM
- monocytes: 120 nCPM
- ocular epithelial cells: 118 nCPM
Immune cell
- neutrophil: 3.6 nTPM
- eosinophil: 2.1 nTPM
- MAIT T-cell: 2.1 nTPM
- naive B-cell: 1.6 nTPM
- NK-cell: 1.6 nTPM
- basophil: 1.4 nTPM
Brain region
- cerebral cortex: 67 nTPM
- white matter: 64 nTPM
- basal ganglia: 62 nTPM
- hippocampal formation: 60 nTPM
- amygdala: 55 nTPM
- pons: 54 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about MARK2.
Disease | AllUniProt
Conditions MARK2 is implicated in, by any mechanism.
- Intellectual developmental disorder, autosomal dominant 76 (MRD76) MIM:621285
Disease | GeneticClinVar
31 pathogenic / likely-pathogenic of 166 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Autism spectrum disorder
- Intellectual developmental disorder, autosomal dominant 76
- Intellectual disability
- Malignant tumor of urinary bladder
- MARK2-associated neurodevelopmental disorder
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.16
- gnomAD pLI
- 1
- gnomAD missense Z
- 4.45
- DepMap mean gene effect
- -0.34
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- autophagy of mitochondrion
- axon development
- establishment of cell polarity
- establishment or maintenance of cell polarity regulating cell shape
- establishment or maintenance of epithelial cell apical/basal polarity
- intracellular signal transduction
- microtubule cytoskeleton organization
- mitochondrion localization
- neuron migration
- positive regulation of neuron projection development
- protein autophosphorylation
- protein phosphorylation
- regulation of axonogenesis
- regulation of cytoskeleton organization
- regulation of microtubule cytoskeleton organization
- regulation of neurofibrillary tangle assembly
- Wnt signaling pathway
Molecular functions
- ATP binding
- cadherin binding
- lipid binding
- magnesium ion binding
- protein kinase activator activity
- protein serine kinase activity
- protein serine/threonine kinase activity
- RNA binding
- tau protein binding
- tau-protein kinase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Protein kinase domain
- Kinase associated domain 1 (KA1)
- Serine/threonine-protein kinase, active site
- Protein kinase-like domain superfamily
- Ubiquitin-associated domain
- Protein kinase, ATP binding site
- KA1 domain/Ssp2, C-terminal
- Serine/threonine-protein kinase MARK 1-4, catalytic domain
- Protein kinase domain
- UBA/TS-N domain
- Kinase associated domain 1
KeywordsUniProt
- Alternative promoter usage
- ATP-binding
- Autism spectrum disorder
- Cell membrane
- Cell projection
- Cytoplasm
- Cytoskeleton
- Developmental protein
- Differentiation
- Intellectual disability
- Kinase
- Lipid-binding
- Magnesium
- Membrane
- Metal-binding
- Nucleotide-binding
- Phosphoprotein
- Serine/threonine-protein kinase
- Transferase
- Wnt signaling pathway
InteractionsUniProt · HPA
Protein binding partners of MARK2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads MARK2 as an antibody target. Whether an autoantibody or antibody against MARK2 could matter depends on whether native MARK2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
MARK2 is annotated at the cell surface, where native MARK2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label MARK2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...